Stefanie Engler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stefanie Engler has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Achim Weber
University of Zurich Zurich Switzerland
1 shared publication - Bernd Bodenmiller
Department of Quantitative Biomedicine, University of Zurich, Zurich, Switzerland
1 shared publication - Claudia Corrò
Translational Research Center in Onco-Hematology, Department of Medicine, Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland
1 shared publication - Holger Moch
Department of Pathology and Molecular Pathology, University of Zurich and University Hospital, Zurich, Switzerland
1 shared publication - Ian James Frew
Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg, Germany
1 shared publication - Marc Eammonn Healy
Department of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland
1 shared publication
Latest Publications
- Open Access
- 18 March 2019
- Published by Wiley in The Journal of Pathology
- Vol. 248 (3) , 377-389
IL‐8 and CXCR1 expression is associated with cancer stem cell‐like properties of clear cell renal cancer
Recent studies suggest that clear cell renal cell carcinoma (ccRCC) possesses a rare population of cancer stem cells (CSCs) that might contribute to tumor heterogeneity, metastasis and therapeutic resistance. Nevertheless, their relevance for renal cancer is still unclear. In this study, we successfully isolated CSCs from established human ccRCC cell lines. CSCs displayed high expression of the chemokine IL‐8 and its receptor CXCR1. While recombinant IL‐8 significantly increased CSC number and properties in vitro, CXCR1 inhibition using an anti‐CXCR1 antibody or repertaxin significantly reduced these features. After injection into immune‐deficient mice, CSCs formed primary tumors that metastasized to the lung and liver. All xenografted tumors in mice expressed high levels of IL‐8 and CXCR1. Furthermore, IL‐8/CXCR1 expression significantly correlated with decreased overall survival in ccRCC patients. These results suggest that the IL‐8/CXCR1 phenotype is associated with CSC‐like properties in renal cancer. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
- 18 March 2019
- Published by Wiley in The Journal of Pathology
- Vol. 248 (3) , 377-389
Open AccessIL‐8 and CXCR1 expression is associated with cancer stem cell‐like properties of clear cell renal cancer
Recent studies suggest that clear cell renal cell carcinoma (ccRCC) possesses a rare population of cancer stem cells (CSCs) that might contribute to tumor heterogeneity, metastasis and therapeutic resistance. Nevertheless, their relevance for renal cancer is still unclear. In this study, we successfully isolated CSCs from established human ccRCC cell lines. CSCs displayed high expression of the chemokine IL‐8 and its receptor CXCR1. While recombinant IL‐8 significantly increased CSC number and properties in vitro, CXCR1 inhibition using an anti‐CXCR1 antibody or repertaxin significantly reduced these features. After injection into immune‐deficient mice, CSCs formed primary tumors that metastasized to the lung and liver. All xenografted tumors in mice expressed high levels of IL‐8 and CXCR1. Furthermore, IL‐8/CXCR1 expression significantly correlated with decreased overall survival in ccRCC patients. These results suggest that the IL‐8/CXCR1 phenotype is associated with CSC‐like properties in renal cancer. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.